Pharma BD Deal Intelligence
GSK signs licence deal for Hansoh cancer drug HS-20093 B7-H3 ADC worldwide rights excluding China.
FDA granted Orphan Drug Designation to risvutatug rezetecan (GSK'227) for SCLC (10 Dec 2025) — the fifth regulatory designation for the B7-H3 ADC.
GSK's B7-H3-targeted ADC risvutatug rezetecan (Ris-Rez) granted Orphan Drug Designation for SCLC by Japan's MHLW (23 Mar 2026) — the sixth regulatory…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
GSK licensed HS-20093, a B7-H3 targeted ADC with topoisomerase inhibitor payload, from Hansoh Pharma. GSK paid $185M upfront with up to $1.525B in success-based milestones plus tiered royalties. GSK obtained exclusive worldwide rights excluding Greater China. This was GSK's second ADC deal with Hansoh in two months.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GSK plc / Hansoh Pharmaceutical Group Co. Ltd. (this deal) | 2023 | $1.7B | 74 |
| GSK plc / SmithKline Beecham | 2000 | $12.0B | 79 |
| GSK plc / Pfizer Inc. | 2018 | $0.0M | 77 |
| GSK plc / Novartis AG | 2014 | $16.0B | 76 |
| GSK plc / Nuvalent, Inc. | 2026 | $10.6B | 70 |
| GSK plc / Sierra Oncology Inc. | 2022 | $1.9B | 70 |
| GSK plc / Human Genome Sciences | 2012 | $3.6B | 70 |
← Browse all deals · How we score deals
More: 2023 deals · GSK plc deals · Oncology deals